SPECIAL FEATURES

CCR Pediatric Oncology Series
Complimentary access to this online-only series of articles from the AACR Childhood Cancer Predisposition Workshop:
clincancerres.aacrjournals.org/pediatricseries

- e91 Genetic Counselor Recommendations for Cancer Predisposition Evaluation and Surveillance in the Pediatric Oncology Patient

- e98 Retinoblastoma and Neuroblastoma Predisposition and Surveillance

- e107 Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood

- e115 Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma

- e123 Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood

Highlights of This Issue 3227

CCR Translations

3229 The Microbiota: A New Variable Impacting Cancer Treatment Outcomes
  Jessica L. Fessler and Thomas F. Gajewski
  See related article, p. 3263

Reviews

3232 Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair
  Aimee Bence Lin, Samuel C. McNeely, and Richard P. Beckmann

3241 The Promise of Targeting Macrophages in Cancer Therapy
  J. Martin Brown, Lawrence Recht, and Samuel Strober

3251 Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors
  Debu Tripathy, Aditya Bardia, and William R. Sellers

PERSPECTIVE

3263 Can Consideration of the Microbiome Improve Antimicrobial Utilization and Treatment Outcomes in the Oncology Patient?
  Jessica R. Galloway-Petia, Robert R. Jenq, and Samuel A. Shelburne
  See related commentary, p. 3229

CANCER THERAPY: CLINICAL

3269 First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
PERSONALIZED MEDICINE AND IMAGING

3325 Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity

3334 Unsupervised Clustering of Quantitative Image Phenotypes Reveals Breast Cancer Subtypes with Distinct Prognoses and Molecular Pathways
Jia Wu, Yi Cui, Xiaoli Sun, Guohong Cao, Bailiang Li, Debra M. Ikeda, Allison W. Kuiran, and Ruijiang Li

CANCER THERAPY: PRECLINICAL

3371 PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
Jiqing Sai, Philip Owens, Sergey V. Novitskiy, Oriana E. Hawkins, Anna E. Vilgelm, Jinming Yang, Tammy Sobolik, Nicole Lavender, Andrew C. Johnson, Colt McClain, Gregory D. Ayers, Mark C. Kelley, Melinda Sanders, Ingrid A. Mayer, Harold L. Moses, Mark Boothby, and Ann Richmond
ABOUT THE COVER

The cover shows a section of a PyMT breast tumor treated with the pan PI3K inhibitor BKM120 (30 mg/kg daily) and PD-1-blocking antibody (100 µg twice a week). H&E staining reveals an extensive infiltration of immune cells into the treated tumors, which was associated with reduction in tumor growth and was not observed in control tumors. For details, see the article by Sai and colleagues on page 3371 of this issue.